首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   31652篇
  免费   1837篇
  国内免费   77篇
耳鼻咽喉   448篇
儿科学   1278篇
妇产科学   925篇
基础医学   5133篇
口腔科学   725篇
临床医学   2585篇
内科学   6217篇
皮肤病学   782篇
神经病学   3359篇
特种医学   1359篇
外国民族医学   14篇
外科学   4160篇
综合类   144篇
一般理论   4篇
预防医学   1771篇
眼科学   629篇
药学   1776篇
中国医学   32篇
肿瘤学   2225篇
  2023年   152篇
  2022年   241篇
  2021年   481篇
  2020年   340篇
  2019年   450篇
  2018年   556篇
  2017年   462篇
  2016年   623篇
  2015年   665篇
  2014年   853篇
  2013年   1092篇
  2012年   1647篇
  2011年   1706篇
  2010年   893篇
  2009年   939篇
  2008年   1542篇
  2007年   1602篇
  2006年   1517篇
  2005年   1548篇
  2004年   1304篇
  2003年   1292篇
  2002年   1210篇
  2001年   950篇
  2000年   972篇
  1999年   852篇
  1998年   426篇
  1997年   328篇
  1996年   268篇
  1995年   243篇
  1994年   209篇
  1993年   214篇
  1992年   487篇
  1991年   513篇
  1990年   501篇
  1989年   418篇
  1988年   398篇
  1987年   412篇
  1986年   402篇
  1985年   395篇
  1984年   276篇
  1983年   215篇
  1981年   148篇
  1979年   262篇
  1978年   184篇
  1977年   156篇
  1976年   152篇
  1975年   166篇
  1974年   195篇
  1973年   168篇
  1972年   155篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
ObjectiveSpinal cord stimulation (SCS) is an effective treatment in failed back surgery syndrome (FBSS). We studied the effect of preimplantation opioid use on SCS outcome and the effect of SCS on opioid use during a two-year follow-up period.Materials and methodsThe study cohort included 211 consecutive FBSS patients who underwent an SCS trial from January 1997 to March 2014. Participants were divided into groups, which were as follows: 1) SCS trial only (n = 47), 2) successful SCS (implanted and in use throughout the two-year follow-up period, n = 131), and 3) unsuccessful SCS (implanted but later explanted or revised due to inadequate pain relief, n = 29). Patients who underwent explantation for other reasons (n = 4) were excluded. Opioid purchase data from January 1995 to March 2016 were retrieved from national registries.ResultsHigher preimplantation opioid doses associated with unsuccessful SCS (ROC: AUC = 0.66, p = 0.009), with 35 morphine milligram equivalents (MME)/day as the optimal cutoff value. All opioids were discontinued in 23% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.004). Strong opioids were discontinued in 39% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.04). Mean opioid dose escalated from 18 ± 4 MME/day to 36 ± 6 MME/day with successful SCS and from 22 ± 8 MME/day to 82 ± 21 MME/day with unsuccessful SCS (p < 0.001).ConclusionsHigher preimplantation opioid doses were associated with SCS failure, suggesting the need for opioid tapering before implantation. With continuous SCS therapy and no explantation or revision due to inadequate pain relief, 39% of FBSS patients discontinued strong opioids, and 23% discontinued all opioids. This indicates that SCS should be considered before detrimental dose escalation.  相似文献   
2.
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz - Akteure der öffentlichen Gesundheit (Public Health) tragen wesentlich zu Gesundheitsschutz, -förderung und...  相似文献   
3.
4.
5.
In May 2017, the Health and Environmental Sciences Institute's Genetic Toxicology Technical Committee hosted a workshop to discuss whether mode of action (MOA) investigation is enhanced through the application of the adverse outcome pathway (AOP) framework. As AOPs are a relatively new approach in genetic toxicology, this report describes how AOPs could be harnessed to advance MOA analysis of genotoxicity pathways using five example case studies. Each of these genetic toxicology AOPs proposed for further development includes the relevant molecular initiating events, key events, and adverse outcomes (AOs), identification and/or further development of the appropriate assays to link an agent to these events, and discussion regarding the biological plausibility of the proposed AOP. A key difference between these proposed genetic toxicology AOPs versus traditional AOPs is that the AO is a genetic toxicology endpoint of potential significance in risk characterization, in contrast to an adverse state of an organism or a population. The first two detailed case studies describe provisional AOPs for aurora kinase inhibition and tubulin binding, leading to the common AO of aneuploidy. The remaining three case studies highlight provisional AOPs that lead to chromosome breakage or mutation via indirect DNA interaction (inhibition of topoisomerase II, production of cellular reactive oxygen species, and inhibition of DNA synthesis). These case studies serve as starting points for genotoxicity AOPs that could ultimately be published and utilized by the broader toxicology community and illustrate the practical considerations and evidence required to formalize such AOPs so that they may be applied to genetic toxicity evaluation schemes. Environ. Mol. Mutagen. 61:114–134, 2020. © 2019 Wiley Periodicals, Inc.  相似文献   
6.
Hawi  N.  von Falck  C.  Krettek  C.  Meller  R. 《Der Unfallchirurg》2019,122(12):944-949
Die Unfallchirurgie - Zur Diagnostik von Schultergelenkerkrankungen wird routinemäßig die Magnetresonanztomographie (MRT) durchgeführt. Diese kann entsprechend der klinischen...  相似文献   
7.
8.
9.
10.
Setting goals to maintain hope.   总被引:3,自引:0,他引:3  
  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号